Roche buys Telavant Holdings for $7.1 billion Roche said today it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from US biotech firm Roivant Holdings and Pfizer. Business • 23 Oct 23
Roche buys Telavant Holdings for $7.1 billion Roche said today it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from US biotech firm Roivant Holdings and Pfizer. Business • 23 Oct 23
